Xenetic Biosciences is a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen® for creating next generation biologic drugs by extending the efficacy, safety and half-life of biologic drugs and OncoHist® for the development of novel oncology drugs focused on orphan indications.

 

Technology Platforms
PolyXen
polyxen

Enhanced performance of peptide and protein drugs using polysialylation.

More about PolyXen

oncohist
imuxen

OncoHist™ has been established as a novel patent-protected platform technology...

More about OncoHist

If you wish the view the Scheme Document and other related Documents, please click here.

Product Pipeline

Xenetic is developing a biopharmaceutical pipeline with a multi-billion dollar market potential.

View our product candidates

Our Partnerships

Xenetic has collaborations with leading global biopharma companies, including Baxter International

More about the projects with some of our partners